---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-25-052771"
form_type: "8-K"
ticker: "MDT"
cik: "0001613103"
company_name: "Medtronic plc"
filed_at: "2025-11-18T23:59:59+00:00"
generated_at: "2026-05-16T18:47:43.359267+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Medtronic Q2 FY26: Revenue $9.0B (+5.5% organic), non-GAAP EPS $1.36 (+8%); raises FY26 guidance

## Summary
- Q2 organic revenue growth 5.5% (beat guidance midpoint by 75 bps); GAAP EPS $1.07 (+8%), non-GAAP EPS $1.36 (+8%).
- Cardiovascular revenue $3.44B (+9.3% organic); Cardiac Ablation Solutions up 71% on PFA portfolio.
- Raises FY26 organic revenue growth guidance to ~5.5% (from ~5.0%); non-GAAP EPS guidance to $5.62-$5.66.
- Received FDA approval for Altaviva device for urge UI; CMS NCD for Symplicity hypertension procedure.
- Diabetes revenue $757M (+7.1% organic); Hugo robotic surgery study met safety and effectiveness endpoints.

## SEC filing metadata
- accession: 0001628280-25-052771
- form_type: 8-K
- ticker: MDT
- cik: 0001613103
- company_name: Medtronic plc
- filed_at: 2025-11-18T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1613103/000162828025052771/0001628280-25-052771-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1613103/000162828025052771/mdt-20251118.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-25-052771
- JSON: https://secwatch.observer/filing/0001628280-25-052771.json
- Plain text: https://secwatch.observer/filing/0001628280-25-052771.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.